IgA Nephropathy Disease Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Test (Blood Test, Urine Test, Kidney Biopsy, Iothalamate Clearance Test, Others), By Treatment Type (Corticosteroids, Immunosuppressive Drugs, ACE Inhibitors And ARBs, Diet Change, Therapy), And By Geography - Forecasts From 2022 To 2027

  • Published : Mar 2022
  • Report Code : KSI061612300
  • Pages : 132

The IgA Nephropathy disease treatment market is projected to grow at a CAGR of 17.27% during the forecast period to reach US$391.608 million by 2027, from US$128.428 million in 2020.

IgA Nephropathy (IgAN), commonly known as Berger's disease, is rare autoimmune kidney disease. It obstructs blood filtration in the small blood channels of the kidneys. IgA Nephropathy is caused by an abnormal protein that kills the filtering unit (glomerulus) inside the kidneys. It is thought that 20–40% of people with IgA Nephropathy may develop end-stage kidney failure, requiring dialysis or kidney transplantation. It can manifest itself in many ways, from asymptomatic microscopic hematuria to rapidly progressive GN. The typical mode of presentation varies depending on the age group and biopsy practice patterns. IgA Nephropathy disease treatment consists of medications that assist manage symptoms such as high blood pressure, protein in the urine, and edema, as well as slow the progression of the disease. Though the actual etiology of the illness is unknown, a variety of immunosuppressants, or immune-suppressing drugs, such as steroids, are being considered.

One of the key reasons driving the IgA Nephropathy disease treatment market during the forecast period is the rising number of cases of IgA Nephropathy around the world. The increasing cases have influenced the demand for novel medications for IgA Nephropathy treatment. The growing interest in a better knowledge of illness pathophysiology and the lack of particular treatment options will propel the market forward throughout the forecast period. Furthermore, rising health awareness will fuel market expansion due to early disease detection.

IgA Nephropathy disease affects a small, heterogeneous, and widely dispersed patient population, making clinical trial enrolment, design, and replication more difficult. This process wastes crucial time, delays access to new medicines, and causes significant losses. Measuring clinical trial outcomes in patients is difficult due to the wide range of clinical presentations and histories. Variables such as age, disease progression, and severity influence reported outcomes, whether clinician-reported, observer-reported, or patient-reported. Given the relative rarity of IgA Nephropathy, robust trials have generally been hampered by limited enrolment, and there has been a scarcity of worldwide recruiting clinical research trials.

Key Developments

  • On December 20, 2021, Calliditas Therapeutics AB announced that the US Food and Drug Administration approved budesonide (TARPEYO) delayed-release capsules for the treatment of proteinuria in people with primary immunoglobulin. Atrasentan is a powerful and selective endothelin A receptor inhibitor that could be used to treat IgA nephropathy (IgAN) and other proteinuric glomerular disorders. Chinook Therapeutics hopes to start a phase 3 trial of Atrasentan in patients with IgA Nephropathy who are at high risk of renal function deterioration in early 2021. Travere Therapeutics, Inc. published positive topline interim findings for sparsentan, an experimental pharmaceutical candidate for treating IgA nephropathy, on August 16, 2021.

By tests, the IgA Nephropathy disease treatment market is segmented into blood tests, urine tests, glomerular filtration rate (GFR), kidney biopsy, and others.

By treatment type, the IgA Nephropathy disease treatment market is segmented into corticosteroids, therapy, immunosuppressive drugs, ACE inhibitors and ARBs, and diet change. Two of the most frequent IgA Nephropathy treatments are angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin-receptor blockers (ARBs).

By geography, the IgA Nephropathy disease treatment market is segmented into five regions North America, Europe, South America, the Middle East and Africa, and the Asia Pacific regions. Because of the increased demand for IgA nephropathy by academics and scientists, North America is projected to dominate the market. The United States is expected to hold a major market share as the disease is one of the main reasons for acute nephritis among young people in the region. Due to advancement and increased demand for more IgA nephropathy products and services, Europe is predicted to grow substantially. The Asia-Pacific region is predicted to grow at the quickest CAGR during the forecast period, as demand for modern IgA nephropathy products increases in countries like China and the Asia Pacific region.

COVID-19 Insights

Due to the COVID-19 pandemic lockdown, measures were placed, preventing patient movement and likely identification and overburdening healthcare systems. The COVID 19 epidemic would lead to an extremely slow turnaround time for patients undergoing selected procedures. Even if fully vaccinated, those with renal illness at any stage and kidney transplant recipients may not have as much protection against the virus. COVID-19 sickness appears to be more severe in older adults and people with kidney diseases such as IgA Nephropathy or other severe chronic medical conditions.

IgA Nephropathy Disease Treatment Market Scope:

Report Metric Details
 Market size value in 2020  US$128.428 million
 Market size value in 2027  US$391.608 million
 Growth Rate  CAGR of 17.27% from 2019 to 2026
 Base year  2019
 Forecast period  2022–2027
 Forecast Unit (Value)  USD Million
 Segments covered  Test, Treatment Type, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered Travere Therapeutics Inc., Calliditas Therapeutics AB, Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Merck KGaA, Darmstadt, Germany, Reata Pharmaceuticals, Inc., Ionis Pharmaceuticals, Apellis Pharmaceuticals
 Customization scope  Free report customization with purchase


Key Market Segments

  • By Test
    • Blood Test
    • Urine test
    • Kidney biopsy
    • Iothalamate clearance test
    • Others
  • By Treatment Type
    • Corticosteroids
    • Immunosuppressive drugs
    • ACE inhibitors and ARBs
    • Diet change
    • Therapy
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the IgA nephropathy disease treatment market size by 2027?
A1. The global IgA nephropathy disease treatment market is projected to reach a market size of US$391.608 millionn by 2027.

Q2. What is the size of the global IgA nephropathy disease treatment market?
A2. IgA Nephropathy Disease Treatment Market was valued at US$128.428 million in 2020.

Q3. What are the growth prospects for the IgA nephropathy disease treatment market?
A3. The IgA nephropathy disease treatment market is projected to grow at a CAGR of 17.27% over the forecast period.

Q4. Which region holds the largest market share in the IgA nephropathy disease treatment market?
A4. North America is projected to dominate the IgA nephropathy disease treatment market due to the increased demand for IgA nephropathy by academics and scientists in the region. 

Q5. What factors are anticipated to drive the IgA nephropathy disease treatment market growth?
A5. One of the key reasons driving the IgA Nephropathy disease treatment market is the rising number of cases of IgA Nephropathy around the world. 

1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis

5.1. Introduction
5.2. Blood test
5.3. Urine test
5.4. Kidney biopsy
5.5. Iothalamate clearance test
5.6. Others

6.1. Introduction
6.2. Corticosteroids 
6.3. Immunosuppressive drugs
6.4. ACE inhibitors and ARBs
6.5. Diet Change
6.6. Therapy

7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. United Kingdom 
7.4.2. Germany
7.4.3. France
7.4.4. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. Israel
7.5.3. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. Japan
7.6.3. India
7.6.4. South Korea
7.6.5. Others

8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrative
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix

9.1. Travere Therapeutics Inc.
9.2. Calliditas Therapeutics AB
9.3. Omeros
9.4. Novartis Pharmaceuticals
9.5. Chinook Therapeutics, Inc.
9.6. Vera Therapeutics, Inc.
9.7. Merck KGaA, Darmstadt, Germany
9.8. Reata Pharmaceuticals, Inc.
9.9. Ionis Pharmaceuticals
9.10. Apellis Pharmaceuticals

Travere Therapeutics Inc.            

Calliditas Therapeutics AB


Novartis Pharmaceuticals

Chinook Therapeutics, Inc.

Vera Therapeutics, Inc.

Merck KGaA, Darmstadt, Germany

Reata Pharmaceuticals, Inc.

Ionis Pharmaceuticals

Apellis Pharmaceuticals